2022 - Research.com Immunology in United Kingdom Leader Award
1990 - Fellow of the Royal Society, United Kingdom
His primary areas of investigation include Immunology, Antibody, Transplantation, Monoclonal antibody and Antigen. T cell, Immune system, Immune tolerance, Immunotherapy and Immunosuppression are the core of his Immunology study. His Antibody study combines topics from a wide range of disciplines, such as Molecular biology, In vivo and Virology.
His work deals with themes such as CD8 and Bone marrow, which intersect with Transplantation. His Monoclonal antibody research incorporates elements of T lymphocyte, Autoimmune disease, Immunogenicity, Pathology and Immunoglobulin E. He interconnects Immunity and Effector in the investigation of issues within Antigen.
The scientist’s investigation covers issues in Immunology, Monoclonal antibody, Transplantation, Antibody and Antigen. Immune system, T cell, Immune tolerance, Immunosuppression and Bone marrow are the subjects of his Immunology studies. His T cell study combines topics in areas such as Cytotoxic T cell and Cell biology.
His Monoclonal antibody research is multidisciplinary, relying on both T lymphocyte, CD8, In vivo and Immunotherapy. The Antibody study combines topics in areas such as CD3 and Virology. His study in Antigen is interdisciplinary in nature, drawing from both Molecular biology and In vitro.
Immunology, Immune system, FOXP3, Cell biology and Transplantation are his primary areas of study. His research related to Immune tolerance, Antigen, Monoclonal antibody, Antibody and Immunosuppression might be considered part of Immunology. His Monoclonal antibody study deals with Virology intersecting with Transgene.
His biological study spans a wide range of topics, including Cancer research, Regulatory T cell, IL-2 receptor, Cytokine and CD8. Herman Waldmann has included themes like T cell, T cell differentiation and Tolerance induction in his Cell biology study. Transplantation is a subfield of Surgery that Herman Waldmann explores.
His main research concerns Immunology, Cell biology, FOXP3, T cell and Immune system. The concepts of his Immunology study are interwoven with issues in In vivo and Transplantation. His Cell biology research integrates issues from Regulatory T cell, Downregulation and upregulation and CD8.
His studies in FOXP3 integrate themes in fields like IL-2 receptor, Cellular differentiation, Cytokine, Antigen and Receptor. His studies deal with areas such as Interleukin 2 and Biochemistry as well as T cell. His Immune system study incorporates themes from Proinflammatory cytokine and Regulation of gene expression.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Reshaping human antibodies for therapy.
Lutz Riechmann;Michael Clark;Herman Waldmann;Greg Winter.
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen;Evy Vandemeulebroucke;Anette G. Ziegler;Chantal Mathieu.
The New England Journal of Medicine (2005)
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
S P Cobbold;A Jayasuriya;A Nash;T D Prospero.
"Infectious" transplantation tolerance
Shixin Qin;Stephen P. Cobbold;Heather Pope;James Elliott.
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
M Brüggemann;G T Williams;C I Bindon;M R Clark.
Journal of Experimental Medicine (1987)
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
G. Hale;M.R. Clark;R. Marcus;G. Winter.
The Lancet (1988)
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
A Davies;D L Simmons;G Hale;R A Harrison.
Journal of Experimental Medicine (1989)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Jeanette Lundin;Eva Kimby;Magnus Björkholm;Per-Anders Broliden.
Identification of regulatory T cells in tolerated allografts
Luis Graca;Stephen P. Cobbold;Herman Waldmann.
Journal of Experimental Medicine (2002)
The window of therapeutic opportunity in multiple sclerosis : Evidence from monoclonal antibody therapy
A. J. Coles;A. Cox;E. Le Page;J. Jones.
Journal of Neurology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: